DK3456330T3 - Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer - Google Patents

Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer Download PDF

Info

Publication number: DK3456330T3
Authority: DK; Denmark
Prior art keywords: cortexolon; valerat; 17alpha; tumor treatment; tumor
Prior art date: 2014-10-08

Application number

DK18198653.0T

Other languages

English (en)

Inventor

Mara Gerloni

Original Assignee

Cosmo Technologies Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-08

Filing date

2015-10-07

Publication date

2021-07-26

2015-10-07 Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd

2021-07-26 Application granted granted Critical

2021-07-26 Publication of DK3456330T3 publication Critical patent/DK3456330T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

DK18198653.0T 2014-10-08 2015-10-07 Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer DK3456330T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14188063.3A EP3006453A1 (en)	2014-10-08	2014-10-08	17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP15778634.4A EP3204400B1 (en)	2014-10-08	2015-10-07	17a,21-diesters of cortexolone for use in the treatment of tumors

Publications (1)

Publication Number	Publication Date
DK3456330T3 true DK3456330T3 (da)	2021-07-26

Family

ID=51687868

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK15778634.4T DK3204400T3 (da)	2014-10-08	2015-10-07	17alfa,21-diestere af cortexolon til anvendelse i behandling af tumorer
DK18198653.0T DK3456330T3 (da)	2014-10-08	2015-10-07	Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK15778634.4T DK3204400T3 (da)	2014-10-08	2015-10-07	17alfa,21-diestere af cortexolon til anvendelse i behandling af tumorer

Country Status (23)

Country	Link
US (8)	US10231980B2 (da)
EP (4)	EP3006453A1 (da)
JP (5)	JP6735739B2 (da)
KR (5)	KR102712584B1 (da)
CN (5)	CN111285913B (da)
AU (3)	AU2015329999B2 (da)
BR (2)	BR112017007076B1 (da)
CA (3)	CA2960928C (da)
DK (2)	DK3204400T3 (da)
ES (3)	ES2806094T3 (da)
HR (2)	HRP20190194T1 (da)
HU (2)	HUE055143T2 (da)
IL (3)	IL272095B2 (da)
LT (2)	LT3456330T (da)
MX (3)	MX2017004661A (da)
PL (2)	PL3204400T3 (da)
PT (2)	PT3456330T (da)
RS (2)	RS62147B1 (da)
RU (2)	RU2712950C2 (da)
SI (2)	SI3456330T1 (da)
TR (1)	TR201901422T4 (da)
WO (2)	WO2016055537A1 (da)
ZA (2)	ZA201702209B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12226412B2 (en)	2012-05-25	2025-02-18	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en)	2012-05-25	2014-10-14	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP3006453A1 (en)	2014-10-08	2016-04-13	Cosmo Technologies Ltd.	17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
US9943505B2 (en)	2016-09-09	2018-04-17	Corcept Therapeutics, Inc.	Glucocorticoid receptor modulators to treat pancreatic cancer
FI3600282T3 (fi)	2017-03-31	2025-11-07	Corcept Therapeutics Inc	Glukokortikoidireseptorien modulaattoreita kohdunkaulan syövän hoitoon
US11234971B2 (en)	2018-12-19	2022-02-01	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CA3121193C (en)	2018-12-19	2024-03-12	Corcept Therapeutics Incorporated	Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11389432B2 (en)	2018-12-19	2022-07-19	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN110698527B (zh) *	2019-11-19	2022-08-26	湖南新合新生物医药有限公司	一种高纯度氢化可的松-17-戊酸酯的制备方法
CN112028956A (zh) *	2020-09-10	2020-12-04	那路新	合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法
WO2022134033A1 (en)	2020-12-25	2022-06-30	Corcept Therapeutics Incorporated	Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN114113603B (zh) *	2021-06-30	2023-11-17	四川大学华西医院	Cytl1作为胃癌预后标志物的应用
CN116135871A (zh) *	2021-11-16	2023-05-19	石家庄迪斯凯威医药科技有限公司	一种具有抗耐药性的抗菌化合物
KR20250073629A (ko)	2022-10-06	2025-05-27	코어셉트 쎄라퓨틱스 인코포레이티드	글루코코르티코이드 수용체 조절제의 제형
EP4608402A1 (en)	2022-10-28	2025-09-03	Corcept Therapeutics Incorporated	Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE619180A (fr) *	1961-06-24	1962-12-20	Vismara Francesco Spa	17-monoesters de 17 alpha, 21-dihydroxy stéroïdes et leur procédé de préparation
DE1195748B (de) *	1961-06-24	1965-07-01	Vismara Francesco Spa	Verfahren zur Herstellung von 1'-substituierten 17alpha, 21-(1'-Alkoxy)-methylendioxysterioden
NL6605514A (da)	1966-04-25	1967-10-26
DE2748442C3 (de)	1977-10-26	1981-08-27	Schering Ag Berlin Und Bergkamen, 1000 Berlin	17α-(3-Jodbenzoyloxy)-9α -chlor4-pregnen-3.20-dione, Zwischenprodukte und Verfahren zu ihrer Herstellung, 9α -chlor-17α, 21-dihydroxy-1,4-pregnadien-3,20-dion und dieses enthaltende Arzneimittel
EP0001737B1 (de) *	1977-10-26	1981-01-07	Schering Aktiengesellschaft	17-Alpha-(3-Jodbenzoyloxy)-9-Alpha-chlor-4-pregnen-3.20-dione, deren D-Homo-analoga und Verfahren zu ihrer Herstellung
EP0054786B1 (de) *	1980-12-23	1985-03-20	Schering Aktiengesellschaft	Neue 6-alpha-Methylhydrocortison-Derivate, ihre Herstellung und Verwendung
CY1359A (en)	1981-02-02	1987-08-07	Schering Corp	Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4920216A (en) *	1987-05-28	1990-04-24	The Trustees Of Columbia In The City Of New York	Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates
US5990099A (en)	1988-10-31	1999-11-23	Alcon Laboratories, Inc.	Angiostatic agents and methods and compositions for controlling ocular hypertension
HU210210B (en)	1989-02-07	1995-02-28	Upjohn Co	New process for the 9-alfa dehalogenation of steroids using tin or tin(ii) compounds
DE4121484A1 (de)	1991-06-26	1993-01-07	Schering Ag	Verfahren zur herstellung von 6-methylensteroiden
US6172054B1 (en)	1995-06-15	2001-01-09	Alcon Laboratories, Inc.	Combination therapy for lowering and controlling intraocular pressure
WO2000049993A2 (en)	1999-02-24	2000-08-31	Nitromed, Inc.	Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
CN1173695C (zh) *	1999-06-14	2004-11-03	科斯默股份公司	控制释放与掩蔽味道的口服药物组合物
IT1314184B1 (it)	1999-08-12	2002-12-06	Nicox Sa	Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
CA2428799A1 (en)	2000-11-16	2002-05-23	Alcon Manufacturing, Ltd.	Combination therapy for lowering and controlling intraocular pressure
ITMI20011762A1 (it) *	2001-08-10	2003-02-10	Cosmo Spa	Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
ITMI20051695A1 (it)	2005-09-14	2007-03-15	Cosmo Spa	Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
DE102006059063A1 (de)	2005-12-24	2007-06-28	Bayer Healthcare Ag	Verwendung von BAY 59-3074 zur Herstellung von Medikamenten zur Therapie von Hirntumoren sowie Kombinationen von BAY 59-3074
US7687484B2 (en)	2006-05-25	2010-03-30	Bodor Nicholas S	Transporter enhanced corticosteroid activity
ITMI20071616A1 (it) *	2007-08-03	2009-02-04	Cosmo Spa	Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
CN101397317A (zh)	2007-09-27	2009-04-01	天津药业研究院有限公司	一种新型硝酸酯类甾体化合物
RU2010128239A (ru) *	2007-12-13	2012-01-20	Новартис АГ (CH)	Комбинации терапевтических средств, предназначенных для лечения рака
JP2010515777A (ja)	2008-03-18	2010-05-13	シコールインコーポレイティド	空気感受性ステロイドの精製
US20130140452A1 (en) *	2010-06-01	2013-06-06	Beate Kamlage	Means and methods for diagnosing pancreatic cancer in a subject
EP2701744A4 (en)	2011-03-23	2014-08-20	Pop Test Cortisol Llc	COMBINATION THERAPY
RU2506974C1 (ru)	2012-11-06	2014-02-20	Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации	Способ лечения первично нерезектабельного рака легкого
JOP20200097A1 (ar) *	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
EP3006453A1 (en) *	2014-10-08	2016-04-13	Cosmo Technologies Ltd.	17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors

2014
- 2014-10-08 EP EP14188063.3A patent/EP3006453A1/en not_active Withdrawn
2015
- 2015-10-07 SI SI201531666T patent/SI3456330T1/sl unknown
- 2015-10-07 KR KR1020237011743A patent/KR102712584B1/ko active Active
- 2015-10-07 PL PL15778634T patent/PL3204400T3/pl unknown
- 2015-10-07 PL PL18198653T patent/PL3456330T3/pl unknown
- 2015-10-07 US US15/517,659 patent/US10231980B2/en active Active
- 2015-10-07 CN CN202010134553.1A patent/CN111285913B/zh active Active
- 2015-10-07 US US15/517,653 patent/US10183030B2/en active Active
- 2015-10-07 HU HUE18198653A patent/HUE055143T2/hu unknown
- 2015-10-07 BR BR112017007076-6A patent/BR112017007076B1/pt active IP Right Grant
- 2015-10-07 AU AU2015329999A patent/AU2015329999B2/en active Active
- 2015-10-07 WO PCT/EP2015/073176 patent/WO2016055537A1/en not_active Ceased
- 2015-10-07 CA CA2960928A patent/CA2960928C/en active Active
- 2015-10-07 BR BR112017007078A patent/BR112017007078A2/pt not_active Application Discontinuation
- 2015-10-07 CN CN202211571443.7A patent/CN116102604A/zh active Pending
- 2015-10-07 EP EP15775455.7A patent/EP3204012B1/en active Active
- 2015-10-07 CN CN201580060690.2A patent/CN107001406B/zh active Active
- 2015-10-07 HR HRP20190194TT patent/HRP20190194T1/hr unknown
- 2015-10-07 MX MX2017004661A patent/MX2017004661A/es unknown
- 2015-10-07 ES ES15775455T patent/ES2806094T3/es active Active
- 2015-10-07 JP JP2017518978A patent/JP6735739B2/ja active Active
- 2015-10-07 DK DK15778634.4T patent/DK3204400T3/da active
- 2015-10-07 LT LTEP18198653.0T patent/LT3456330T/lt unknown
- 2015-10-07 RU RU2017115771A patent/RU2712950C2/ru active
- 2015-10-07 HU HUE15778634A patent/HUE041503T2/hu unknown
- 2015-10-07 RS RS20210928A patent/RS62147B1/sr unknown
- 2015-10-07 IL IL272095A patent/IL272095B2/en unknown
- 2015-10-07 TR TR2019/01422T patent/TR201901422T4/tr unknown
- 2015-10-07 PT PT181986530T patent/PT3456330T/pt unknown
- 2015-10-07 ES ES18198653T patent/ES2882223T3/es active Active
- 2015-10-07 WO PCT/EP2015/073172 patent/WO2016055533A1/en not_active Ceased
- 2015-10-07 CN CN202211425819.3A patent/CN115671114A/zh active Pending
- 2015-10-07 CN CN201580060711.0A patent/CN107074905B/zh not_active Expired - Fee Related
- 2015-10-07 MX MX2019008063A patent/MX385557B/es unknown
- 2015-10-07 LT LTEP15778634.4T patent/LT3204400T/lt unknown
- 2015-10-07 KR KR1020177011114A patent/KR102248983B1/ko active Active
- 2015-10-07 MX MX2017004660A patent/MX366294B/es active IP Right Grant
- 2015-10-07 ES ES15778634T patent/ES2713699T3/es active Active
- 2015-10-07 RU RU2017115773A patent/RU2712752C2/ru active
- 2015-10-07 AU AU2015330003A patent/AU2015330003A1/en not_active Abandoned
- 2015-10-07 RS RS20190207A patent/RS58607B1/sr unknown
- 2015-10-07 KR KR1020247032041A patent/KR20240149968A/ko active Pending
- 2015-10-07 KR KR1020217002286A patent/KR102520411B1/ko active Active
- 2015-10-07 JP JP2017518340A patent/JP6503057B2/ja active Active
- 2015-10-07 KR KR1020177011239A patent/KR20170063821A/ko not_active Withdrawn
- 2015-10-07 EP EP15778634.4A patent/EP3204400B1/en active Active
- 2015-10-07 CA CA2962746A patent/CA2962746A1/en not_active Abandoned
- 2015-10-07 PT PT15778634T patent/PT3204400T/pt unknown
- 2015-10-07 EP EP18198653.0A patent/EP3456330B1/en active Active
- 2015-10-07 CA CA3160391A patent/CA3160391C/en active Active
- 2015-10-07 DK DK18198653.0T patent/DK3456330T3/da active
- 2015-10-07 SI SI201530614T patent/SI3204400T1/sl unknown
2017
- 2017-03-08 IL IL251028A patent/IL251028B/en active IP Right Grant
- 2017-03-23 IL IL251371A patent/IL251371A0/en unknown
- 2017-03-29 ZA ZA2017/02209A patent/ZA201702209B/en unknown
2018
- 2018-11-23 US US16/199,015 patent/US10646497B2/en active Active
2019
- 2019-01-17 JP JP2019006199A patent/JP7028809B2/ja active Active
- 2019-02-12 US US16/273,575 patent/US20190175618A1/en not_active Abandoned
- 2019-04-12 ZA ZA2019/02320A patent/ZA201902320B/en unknown
2020
- 2020-02-27 AU AU2020201446A patent/AU2020201446B2/en active Active
- 2020-03-16 US US16/820,407 patent/US10993949B2/en active Active
- 2020-05-27 JP JP2020092411A patent/JP2020143140A/ja active Pending
- 2020-12-01 JP JP2020199555A patent/JP2021046418A/ja active Pending
2021
- 2021-04-06 US US17/223,776 patent/US11712443B2/en active Active
- 2021-07-22 HR HRP20211177TT patent/HRP20211177T1/hr unknown
2022
- 2022-12-19 US US18/068,346 patent/US11986484B2/en active Active
2024
- 2024-03-01 US US18/592,730 patent/US20240277731A1/en active Pending

Also Published As

Publication number	Publication date
CN116102604A (zh)	2023-05-12
EP3456330A1 (en)	2019-03-20
MX2017004661A (es)	2017-10-16
KR20240149968A (ko)	2024-10-15
CA3160391A1 (en)	2016-04-14
HRP20190194T1 (hr)	2019-04-19
KR20170063821A (ko)	2017-06-08
RU2017115773A (ru)	2018-11-15
RU2712950C2 (ru)	2020-02-03
KR20210012047A (ko)	2021-02-02
PL3204400T3 (pl)	2019-05-31
CA2962746A1 (en)	2016-04-14
EP3204400B1 (en)	2018-12-12
RU2712752C2 (ru)	2020-01-31
HRP20211177T1 (hr)	2021-10-29
WO2016055533A1 (en)	2016-04-14
US10183030B2 (en)	2019-01-22
MX2017004660A (es)	2017-10-16
IL272095B2 (en)	2023-04-01
IL272095A (en)	2020-03-31
US10993949B2 (en)	2021-05-04
US20170360806A1 (en)	2017-12-21
US20200215080A1 (en)	2020-07-09
RU2020102939A (ru)	2020-05-20
IL272095B (en)	2022-12-01
MX385557B (es)	2025-03-18
BR112017007078A2 (pt)	2017-12-26
US11712443B2 (en)	2023-08-01
JP2019070033A (ja)	2019-05-09
US10646497B2 (en)	2020-05-12
MX366294B (es)	2019-07-04
BR112017007076A2 (pt)	2017-12-26
SI3204400T1 (sl)	2019-04-30
CN107001406B (zh)	2020-03-27
RU2017115773A3 (da)	2019-03-15
RU2017115771A (ru)	2018-11-12
AU2020201446A1 (en)	2020-05-14
ZA201702209B (en)	2019-08-28
US20230128438A1 (en)	2023-04-27
IL251028A0 (en)	2017-04-30
CN111285913B (zh)	2023-01-10
US20190175618A1 (en)	2019-06-13
US20190091240A1 (en)	2019-03-28
US10231980B2 (en)	2019-03-19
HUE055143T2 (hu)	2021-11-29
KR102712584B1 (ko)	2024-10-04
AU2015330003A1 (en)	2017-04-13
ZA201902320B (en)	2022-11-30
EP3204012A1 (en)	2017-08-16
SI3456330T1 (sl)	2021-09-30
CN111285913A (zh)	2020-06-16
RU2017115771A3 (da)	2019-03-11
IL251028B (en)	2020-01-30
US20170304318A1 (en)	2017-10-26
CN115671114A (zh)	2023-02-03
RS62147B1 (sr)	2021-08-31
MX2019008063A (es)	2019-09-11
JP2020143140A (ja)	2020-09-10
BR112017007076B1 (pt)	2023-12-19
DK3204400T3 (da)	2019-03-04
CA3160391C (en)	2024-06-25
KR102248983B1 (ko)	2021-05-10
AU2015329999B2 (en)	2020-01-23
US20240277731A1 (en)	2024-08-22
EP3006453A1 (en)	2016-04-13
TR201901422T4 (tr)	2019-02-21
CN107001406A (zh)	2017-08-01
KR20170063799A (ko)	2017-06-08
PL3456330T3 (pl)	2021-11-15
CA2960928C (en)	2023-10-31
JP7028809B2 (ja)	2022-03-02
EP3204400A1 (en)	2017-08-16
HUE041503T2 (hu)	2019-05-28
LT3456330T (lt)	2021-08-10
ES2806094T3 (es)	2021-02-16
US20210299145A1 (en)	2021-09-30
EP3456330B1 (en)	2021-05-19
PT3204400T (pt)	2019-02-25
LT3204400T (lt)	2019-04-10
JP6735739B2 (ja)	2020-08-05
ES2713699T3 (es)	2019-05-23
KR20230052990A (ko)	2023-04-20
CA2960928A1 (en)	2016-04-14
AU2015329999A1 (en)	2017-04-06
JP6503057B2 (ja)	2019-04-17
CN107074905B (zh)	2019-08-09
EP3204012B1 (en)	2020-06-03
AU2020201446B2 (en)	2021-03-18
JP2017530171A (ja)	2017-10-12
JP2021046418A (ja)	2021-03-25
CN107074905A (zh)	2017-08-18
PT3456330T (pt)	2021-07-13
WO2016055537A1 (en)	2016-04-14
JP2017530184A (ja)	2017-10-12
IL251371A0 (en)	2017-05-29
US11986484B2 (en)	2024-05-21
ES2882223T3 (es)	2021-12-01
RS58607B1 (sr)	2019-05-31
KR102520411B1 (ko)	2023-04-11

Publication	Publication Date	Title
IL283733A (en)	2021-07-29	Methods of cancer treatment using activated t cells
IL296080B1 (en)	2023-08-01	Method for treating cancer
IL255261A0 (en)	2017-12-31	Methods for treating cancer
DK3456330T3 (da)	2021-07-26	Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3185957T3 (da)	2022-08-29	Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3288581T3 (da)	2021-01-11	Fremgangsmåde til behandling af cancer
DK3193929T3 (da)	2019-08-19	Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer
DK3167318T3 (da)	2022-06-13	Polarisationsuafhængig behandling ved integreret fotonik
DK3240801T3 (da)	2021-02-08	Kombinationstumorimmunterapi
DK3227262T3 (da)	2020-08-10	Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
DK3186376T3 (da)	2019-05-06	Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet
DK3221359T3 (da)	2020-06-22	Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
DK3594238T3 (da)	2021-04-19	Antistofsammensætninger til tumorbehandling
DK3110988T3 (da)	2019-07-29	Metoder til behandling af lithiumholdige materialer
DK3286311T3 (da)	2021-05-17	Fremgangsmåde til behandling af maligniteter
HUE038541T2 (hu)	2018-10-29	Rák kezelési módszerek
DK3231444T3 (da)	2020-03-16	Ny behandling
DK3200815T3 (da)	2021-05-10	Fremgangsmåder og sammensætninger til behandling af cancer
HUE050944T2 (hu)	2021-01-28	Kezelési eljárás tradipitant alkalmazásával
DK3122308T3 (da)	2020-01-13	Indretning til behandling af smerte
DK3236960T3 (da)	2025-03-31	Fluralaner til anvendelse i behandling af demodicose
DK3302519T3 (da)	2022-02-28	Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3374497T3 (da)	2021-11-01	Modificerede makrofager til anvendelse i behandlingen af kræft
DK3164123T3 (da)	2020-08-03	Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
PT3134119T (pt)	2018-11-07	Tratamento do cancro